We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: antiviral prophylaxis
MedXY News
EnglishTag

antiviral prophylaxis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Efficacy and Outcomes of Short-Course Perioperative Antiviral Prophylaxis in Hepatitis C Viremic Donor Kidney Transplantation
Infectious DiseasesDirect-Acting Antiviralsantiviral prophylaxis

Efficacy and Outcomes of Short-Course Perioperative Antiviral Prophylaxis in Hepatitis C Viremic Donor Kidney Transplantation

By MedXY|Aug 20, 2026

A 7-day perioperative sofosbuvir/velpatasvir prophylaxis in HCV-positive donor to HCV-negative recipient kidney transplants demonstrated sustained virologic response in over 92% of cases, with favorable 1-year graft survival and function.

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients
Gastroenterologyantiviral prophylaxis
hepatocellular carcinoma

Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients

By MedXY|Jan 12, 2026

A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial ex

Daily High‑Dose Mosnodenvir Significantly Lowers DENV‑3 Viremia in a Human Challenge — Proof‑of‑Concept with Early Resistance Signals
Infectious Diseasesantiviral prophylaxisDengue

Daily High‑Dose Mosnodenvir Significantly Lowers DENV‑3 Viremia in a Human Challenge — Proof‑of‑Concept with Early Resistance Signals

By MedXY|Nov 27, 2025

In a phase 2a human challenge, high‑dose daily mosnodenvir substantially reduced DENV‑3 RNA burden versus placebo without serious adverse events, but treatment‑associated NS4B viral mutations emerged, highlighting efficacy and resistance co

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities